Cargando…

Antithrombotic prophylaxis for surgery-associated venous thromboembolism risk in patients with inherited platelet disorders. The SPATA-DVT Study

Major surgery is associated with an increased risk of venous thromboembolism (VTE), thus the application of mechanical or pharmacologic prophylaxis is recommended. The incidence of VTE in patients with inherited platelet disorders (IPD) undergoing surgical procedures is unknown and no information on...

Descripción completa

Detalles Bibliográficos
Autores principales: Paciullo, Francesco, Bury, Loredana, Noris, Patrizia, Falcinelli, Emanuela, Melazzini, Federica, Orsini, Sara, Zaninetti, Carlo, Abdul-Kadir, Rezan, Obeng-Tuudah, Deborah, Heller, Paula G., Glembotsky, Ana C., Fabris, Fabrizio, Rivera, Jose, Lozano, Maria Luisa, Butta, Nora, Favier, Remi, Cid, Ana Rosa, Fouassier, Marc, Podda, Gian Marco, Santoro, Cristina, Grandone, Elvira, Henskens, Yvonne, Nurden, Paquita, Zieger, Barbara, Cuker, Adam, Devreese, Katrien, Tosetto, Alberto, De Candia, Erica, Dupuis, Arnaud, Miyazaki, Koji, Othman, Maha, Gresele, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327644/
https://www.ncbi.nlm.nih.gov/pubmed/31558677
http://dx.doi.org/10.3324/haematol.2019.227876
_version_ 1783552585915957248
author Paciullo, Francesco
Bury, Loredana
Noris, Patrizia
Falcinelli, Emanuela
Melazzini, Federica
Orsini, Sara
Zaninetti, Carlo
Abdul-Kadir, Rezan
Obeng-Tuudah, Deborah
Heller, Paula G.
Glembotsky, Ana C.
Fabris, Fabrizio
Rivera, Jose
Lozano, Maria Luisa
Butta, Nora
Favier, Remi
Cid, Ana Rosa
Fouassier, Marc
Podda, Gian Marco
Santoro, Cristina
Grandone, Elvira
Henskens, Yvonne
Nurden, Paquita
Zieger, Barbara
Cuker, Adam
Devreese, Katrien
Tosetto, Alberto
De Candia, Erica
Dupuis, Arnaud
Miyazaki, Koji
Othman, Maha
Gresele, Paolo
author_facet Paciullo, Francesco
Bury, Loredana
Noris, Patrizia
Falcinelli, Emanuela
Melazzini, Federica
Orsini, Sara
Zaninetti, Carlo
Abdul-Kadir, Rezan
Obeng-Tuudah, Deborah
Heller, Paula G.
Glembotsky, Ana C.
Fabris, Fabrizio
Rivera, Jose
Lozano, Maria Luisa
Butta, Nora
Favier, Remi
Cid, Ana Rosa
Fouassier, Marc
Podda, Gian Marco
Santoro, Cristina
Grandone, Elvira
Henskens, Yvonne
Nurden, Paquita
Zieger, Barbara
Cuker, Adam
Devreese, Katrien
Tosetto, Alberto
De Candia, Erica
Dupuis, Arnaud
Miyazaki, Koji
Othman, Maha
Gresele, Paolo
author_sort Paciullo, Francesco
collection PubMed
description Major surgery is associated with an increased risk of venous thromboembolism (VTE), thus the application of mechanical or pharmacologic prophylaxis is recommended. The incidence of VTE in patients with inherited platelet disorders (IPD) undergoing surgical procedures is unknown and no information on the current use and safety of thromboprophylaxis, particularly of low-molecular-weight-heparin in these patients is available. Here we explored the approach to thromboprophylaxis and thrombotic outcomes in IPD patients undergoing surgery at VTE-risk participating in the multicenter SPATA study. We evaluated 210 surgical procedures carried out in 155 patients with well-defined forms of IPD (VTE-risk: 31% high, 28.6% intermediate, 25.2% low, 15.2% very low). The use of thromboprophylaxis was low (23.3% of procedures), with higher prevalence in orthopedic and gynecological surgeries, and was related to VTE-risk. The most frequently employed thromboprophylaxis was mechanical and appeared to be effective, as no patients developed thrombosis, including patients belonging to the highest VTE-risk classes. Low-molecular-weight-heparin use was low (10.5%) and it did not influence the incidence of post-surgical bleeding or of antihemorrhagic prohemostatic interventions use. Two thromboembolic events were registered, both occurring after high VTE-risk procedures in patients who did not receive thromboprophylaxis (4.7%). Our findings suggest that VTE incidence is low in patients with IPD undergoing surgery at VTE-risk and that it is predicted by the Caprini score. Mechanical thromboprophylaxis may be of benefit in patients with IPD undergoing invasive procedures at VTE-risk and low-molecular-weight-heparin should be considered for major surgery.
format Online
Article
Text
id pubmed-7327644
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Ferrata Storti Foundation
record_format MEDLINE/PubMed
spelling pubmed-73276442020-07-10 Antithrombotic prophylaxis for surgery-associated venous thromboembolism risk in patients with inherited platelet disorders. The SPATA-DVT Study Paciullo, Francesco Bury, Loredana Noris, Patrizia Falcinelli, Emanuela Melazzini, Federica Orsini, Sara Zaninetti, Carlo Abdul-Kadir, Rezan Obeng-Tuudah, Deborah Heller, Paula G. Glembotsky, Ana C. Fabris, Fabrizio Rivera, Jose Lozano, Maria Luisa Butta, Nora Favier, Remi Cid, Ana Rosa Fouassier, Marc Podda, Gian Marco Santoro, Cristina Grandone, Elvira Henskens, Yvonne Nurden, Paquita Zieger, Barbara Cuker, Adam Devreese, Katrien Tosetto, Alberto De Candia, Erica Dupuis, Arnaud Miyazaki, Koji Othman, Maha Gresele, Paolo Haematologica Articles Major surgery is associated with an increased risk of venous thromboembolism (VTE), thus the application of mechanical or pharmacologic prophylaxis is recommended. The incidence of VTE in patients with inherited platelet disorders (IPD) undergoing surgical procedures is unknown and no information on the current use and safety of thromboprophylaxis, particularly of low-molecular-weight-heparin in these patients is available. Here we explored the approach to thromboprophylaxis and thrombotic outcomes in IPD patients undergoing surgery at VTE-risk participating in the multicenter SPATA study. We evaluated 210 surgical procedures carried out in 155 patients with well-defined forms of IPD (VTE-risk: 31% high, 28.6% intermediate, 25.2% low, 15.2% very low). The use of thromboprophylaxis was low (23.3% of procedures), with higher prevalence in orthopedic and gynecological surgeries, and was related to VTE-risk. The most frequently employed thromboprophylaxis was mechanical and appeared to be effective, as no patients developed thrombosis, including patients belonging to the highest VTE-risk classes. Low-molecular-weight-heparin use was low (10.5%) and it did not influence the incidence of post-surgical bleeding or of antihemorrhagic prohemostatic interventions use. Two thromboembolic events were registered, both occurring after high VTE-risk procedures in patients who did not receive thromboprophylaxis (4.7%). Our findings suggest that VTE incidence is low in patients with IPD undergoing surgery at VTE-risk and that it is predicted by the Caprini score. Mechanical thromboprophylaxis may be of benefit in patients with IPD undergoing invasive procedures at VTE-risk and low-molecular-weight-heparin should be considered for major surgery. Ferrata Storti Foundation 2020-07 /pmc/articles/PMC7327644/ /pubmed/31558677 http://dx.doi.org/10.3324/haematol.2019.227876 Text en Copyright© 2020 Ferrata Storti Foundation Material published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode. Copies of published material are allowed for personal or internal use. Sharing published material for non-commercial purposes is subject to the following conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode, sect. 3. Reproducing and sharing published material for commercial purposes is not allowed without permission in writing from the publisher.
spellingShingle Articles
Paciullo, Francesco
Bury, Loredana
Noris, Patrizia
Falcinelli, Emanuela
Melazzini, Federica
Orsini, Sara
Zaninetti, Carlo
Abdul-Kadir, Rezan
Obeng-Tuudah, Deborah
Heller, Paula G.
Glembotsky, Ana C.
Fabris, Fabrizio
Rivera, Jose
Lozano, Maria Luisa
Butta, Nora
Favier, Remi
Cid, Ana Rosa
Fouassier, Marc
Podda, Gian Marco
Santoro, Cristina
Grandone, Elvira
Henskens, Yvonne
Nurden, Paquita
Zieger, Barbara
Cuker, Adam
Devreese, Katrien
Tosetto, Alberto
De Candia, Erica
Dupuis, Arnaud
Miyazaki, Koji
Othman, Maha
Gresele, Paolo
Antithrombotic prophylaxis for surgery-associated venous thromboembolism risk in patients with inherited platelet disorders. The SPATA-DVT Study
title Antithrombotic prophylaxis for surgery-associated venous thromboembolism risk in patients with inherited platelet disorders. The SPATA-DVT Study
title_full Antithrombotic prophylaxis for surgery-associated venous thromboembolism risk in patients with inherited platelet disorders. The SPATA-DVT Study
title_fullStr Antithrombotic prophylaxis for surgery-associated venous thromboembolism risk in patients with inherited platelet disorders. The SPATA-DVT Study
title_full_unstemmed Antithrombotic prophylaxis for surgery-associated venous thromboembolism risk in patients with inherited platelet disorders. The SPATA-DVT Study
title_short Antithrombotic prophylaxis for surgery-associated venous thromboembolism risk in patients with inherited platelet disorders. The SPATA-DVT Study
title_sort antithrombotic prophylaxis for surgery-associated venous thromboembolism risk in patients with inherited platelet disorders. the spata-dvt study
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327644/
https://www.ncbi.nlm.nih.gov/pubmed/31558677
http://dx.doi.org/10.3324/haematol.2019.227876
work_keys_str_mv AT paciullofrancesco antithromboticprophylaxisforsurgeryassociatedvenousthromboembolismriskinpatientswithinheritedplateletdisordersthespatadvtstudy
AT buryloredana antithromboticprophylaxisforsurgeryassociatedvenousthromboembolismriskinpatientswithinheritedplateletdisordersthespatadvtstudy
AT norispatrizia antithromboticprophylaxisforsurgeryassociatedvenousthromboembolismriskinpatientswithinheritedplateletdisordersthespatadvtstudy
AT falcinelliemanuela antithromboticprophylaxisforsurgeryassociatedvenousthromboembolismriskinpatientswithinheritedplateletdisordersthespatadvtstudy
AT melazzinifederica antithromboticprophylaxisforsurgeryassociatedvenousthromboembolismriskinpatientswithinheritedplateletdisordersthespatadvtstudy
AT orsinisara antithromboticprophylaxisforsurgeryassociatedvenousthromboembolismriskinpatientswithinheritedplateletdisordersthespatadvtstudy
AT zaninetticarlo antithromboticprophylaxisforsurgeryassociatedvenousthromboembolismriskinpatientswithinheritedplateletdisordersthespatadvtstudy
AT abdulkadirrezan antithromboticprophylaxisforsurgeryassociatedvenousthromboembolismriskinpatientswithinheritedplateletdisordersthespatadvtstudy
AT obengtuudahdeborah antithromboticprophylaxisforsurgeryassociatedvenousthromboembolismriskinpatientswithinheritedplateletdisordersthespatadvtstudy
AT hellerpaulag antithromboticprophylaxisforsurgeryassociatedvenousthromboembolismriskinpatientswithinheritedplateletdisordersthespatadvtstudy
AT glembotskyanac antithromboticprophylaxisforsurgeryassociatedvenousthromboembolismriskinpatientswithinheritedplateletdisordersthespatadvtstudy
AT fabrisfabrizio antithromboticprophylaxisforsurgeryassociatedvenousthromboembolismriskinpatientswithinheritedplateletdisordersthespatadvtstudy
AT riverajose antithromboticprophylaxisforsurgeryassociatedvenousthromboembolismriskinpatientswithinheritedplateletdisordersthespatadvtstudy
AT lozanomarialuisa antithromboticprophylaxisforsurgeryassociatedvenousthromboembolismriskinpatientswithinheritedplateletdisordersthespatadvtstudy
AT buttanora antithromboticprophylaxisforsurgeryassociatedvenousthromboembolismriskinpatientswithinheritedplateletdisordersthespatadvtstudy
AT favierremi antithromboticprophylaxisforsurgeryassociatedvenousthromboembolismriskinpatientswithinheritedplateletdisordersthespatadvtstudy
AT cidanarosa antithromboticprophylaxisforsurgeryassociatedvenousthromboembolismriskinpatientswithinheritedplateletdisordersthespatadvtstudy
AT fouassiermarc antithromboticprophylaxisforsurgeryassociatedvenousthromboembolismriskinpatientswithinheritedplateletdisordersthespatadvtstudy
AT poddagianmarco antithromboticprophylaxisforsurgeryassociatedvenousthromboembolismriskinpatientswithinheritedplateletdisordersthespatadvtstudy
AT santorocristina antithromboticprophylaxisforsurgeryassociatedvenousthromboembolismriskinpatientswithinheritedplateletdisordersthespatadvtstudy
AT grandoneelvira antithromboticprophylaxisforsurgeryassociatedvenousthromboembolismriskinpatientswithinheritedplateletdisordersthespatadvtstudy
AT henskensyvonne antithromboticprophylaxisforsurgeryassociatedvenousthromboembolismriskinpatientswithinheritedplateletdisordersthespatadvtstudy
AT nurdenpaquita antithromboticprophylaxisforsurgeryassociatedvenousthromboembolismriskinpatientswithinheritedplateletdisordersthespatadvtstudy
AT ziegerbarbara antithromboticprophylaxisforsurgeryassociatedvenousthromboembolismriskinpatientswithinheritedplateletdisordersthespatadvtstudy
AT cukeradam antithromboticprophylaxisforsurgeryassociatedvenousthromboembolismriskinpatientswithinheritedplateletdisordersthespatadvtstudy
AT devreesekatrien antithromboticprophylaxisforsurgeryassociatedvenousthromboembolismriskinpatientswithinheritedplateletdisordersthespatadvtstudy
AT tosettoalberto antithromboticprophylaxisforsurgeryassociatedvenousthromboembolismriskinpatientswithinheritedplateletdisordersthespatadvtstudy
AT decandiaerica antithromboticprophylaxisforsurgeryassociatedvenousthromboembolismriskinpatientswithinheritedplateletdisordersthespatadvtstudy
AT dupuisarnaud antithromboticprophylaxisforsurgeryassociatedvenousthromboembolismriskinpatientswithinheritedplateletdisordersthespatadvtstudy
AT miyazakikoji antithromboticprophylaxisforsurgeryassociatedvenousthromboembolismriskinpatientswithinheritedplateletdisordersthespatadvtstudy
AT othmanmaha antithromboticprophylaxisforsurgeryassociatedvenousthromboembolismriskinpatientswithinheritedplateletdisordersthespatadvtstudy
AT greselepaolo antithromboticprophylaxisforsurgeryassociatedvenousthromboembolismriskinpatientswithinheritedplateletdisordersthespatadvtstudy